2. Academic Validation
  3. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo

  • Cancer Cell. 2012 Dec 11;22(6):812-24. doi: 10.1016/j.ccr.2012.11.003.
Lorena Fontan 1,  Chenghua Yang,  Venkataraman Kabaleeswaran,  Laurent Volpon,  Michael J Osborne,  Elena Beltran,  Monica Garcia,  Leandro Cerchietti,  Rita Shaknovich,  Shao Ning Yang,  Fang Fang,  Randy D Gascoyne,  Jose Angel Martinez-Climent,  J Fraser Glickman,  Katherine Borden,  Hao Wu,  Ari Melnick
Affiliations

Affiliation

  • 1 Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10021, USA.
PMID: 23238016 DOI: 10.1016/j.ccr.2012.11.003
Abstract

MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. We developed a MALT1 activity assay and identified chemically diverse MALT1 inhibitors. A selected lead compound, MI-2, featured direct binding to MALT1 and suppression of its Protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates. This was accompanied by NF-κB reporter activity suppression, c-Rel nuclear localization inhibition, and NF-κB target gene downregulation. Most notably, MI-2 was nontoxic to mice, and displayed selective activity against ABC-DLBCL cell lines in vitro and xenotransplanted ABC-DLBCL tumors in vivo. The compound was also effective against primary human non-germinal center B cell-like DLBCLs ex vivo.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z